HomeAI · summaries
Storia in 4 fonti
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a high risk for recurrence after nephrectomy, according to a press release.The approval allows belzutifan (Welireg, Merck) to be used in combination with pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck).
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a high risk for recurrence after nephrectomy, according…
- ·
medpagetoday.com
Adjuvant Combination for Kidney Cancer Gets FDA's Blessing
Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
